ALTEOGEN Inc.

Alteogen Inc. and Daiichi Sankyo enter an exclusive license agreement for ALT-B4, enabling subcutaneous ENHERTU® development. Alteogen to receive upfront and milestone payments, plus royalties on sales.

Alteogen CEO Park Soon-jae's success is attributed to his focus on core business and timely adaptation to global trends, transforming the company from a small lab to a leading bio firm. His strategy of short-term biosimilar exports and long-term 'bio-better' development has led to significant growth, supported by key investors.

Alteogen signed an exclusive license agreement with Daiichi Sankyo to develop and commercialize a subcutaneous version of Enhertu, an ADC cancer treatment, using Alteogen’s ALT-B4 technology. Daiichi Sankyo will pay $20 million upfront and up to $280 million in additional payments based on milestones, with royalties on net sales. This marks the first global attempt to convert ADCs into subcutaneous formulations, potentially reducing side effects and improving efficacy.

Top 1% equity investors net bought Alteogen, BHI, and Hanall Biopharma, while net selling CSwind, Samsung Electronics, and HD Hyundai Electric. Alteogen plans to launch drug 'Tergase' this year, and BHI's stock rose due to iM Securities' report on nuclear and natural gas power demand. CSWind's stock fluctuates with U.S. election dynamics, and Samsung Electronics' stock rise prompts profit realization.

Alteogen plans to launch its self-developed drug 'tergase' in Korea by year-end, partnering with PharmaResearch for sales. Tergase, a human-derived hyaluronidase, aims to address safety concerns over existing animal-derived products, potentially transforming the industry. Alteogen seeks to diversify its sales from technology exports to drug sales, targeting 100 billion won in global sales by 2030.

Alteogen plans to launch its drug 'tergase' in Korea this year, partnering with PharmaResearch for sales. Tergase, a human-derived hyaluronidase, aims to reach 100 billion won in global sales by 2030.

Trastuzumab biosimilars market to grow from $4.27B in 2023 to $5.43B in 2024, reaching $14.69B by 2028, driven by market expansion, patent expirations, and competitive pricing.

The ADC market, driven by technological advancements and personalized medicine, is expected to reach ~USD 26 billion by 2030 with a CAGR of ~14%. North America leads due to high cancer incidence and strong biopharmaceutical sector. Key players include F. Hoffmann-La Roche Ltd, DAIICHI SANKYO COMPANY, LIMITED, and Pfizer Inc. The market is dynamic, influenced by regulatory frameworks and innovation in linker technologies and payloads.

South Korea's tech sector shows mixed performance, but global forecasts suggest optimism. Key tech companies like Bioneer, EuBiologics, and Daeduck Electronics exhibit strong revenue and earnings growth, driven by R&D investments and market adaptability.

The KOSPI index nears 2,600 points amid global uncertainties, highlighting growth companies with high insider ownership. Key companies include Intellian Technologies, trading 40.2% below fair value with 33.4% annual revenue growth; ALTEOGEN, trading 70.4% below fair value with 64.2% annual revenue growth; and Di Dong Il, with 36.44% annual earnings growth despite moderate revenue growth.